Study directory

Mental health studies with practical context.

Public study records, presented in a clearer and more patient-friendly format for mental health research discovery.

Back to overview
23847studies shown
Showing 22,465-22,476 of 23,847
Drug study icon
TerminatedNCT05213143

The Safety and Efficacy of Lurasidone In Subjects With Schizophrenia Switched From Olanzapine

This study exists to explore whether this type of care could improve care and understanding. Researchers are trying to understand what this type of care could change in day-to-day care and decision-making.

In Beijing
SchizophreniaDrugA study involving a medication or substance.From 18 Years to 65 Years
Countries
China
Sponsor
Marubeni Pharmaceuticals (Suzhou) Co., Ltd.
Condition
Schizophrenia
Drug study icon
CompletedNCT05011669

The Safety and Efficacy of Lurasidone With Different Initiation Dose in Chinese Acute Phase people with Schizophrenia

This study exists to understand whether a medication treatment is both safe enough and useful enough to take further. For people living with Schizophrenia, that matters because care needs to work in daily life, not just in theory.

In Beijing
SchizophreniaDrugFrom 18 Years to 65 Years
Countries
China
Sponsor
Marubeni Pharmaceuticals (Suzhou) Co., Ltd.
Condition
Schizophrenia
Drug study icon
CompletedNCT03324581

The Safety and Efficacy of OPC-64005 in the Treatment of Adult Attention-deficit/Hyperactivity Disorder

This study exists to understand whether the medication OPC-64005 is both safe enough and useful enough to take further. Researchers are trying to understand whether the medication OPC-64005 can improve attention, thinking, or day-to-day functioning.

Multiple locations, including Beverly Hills
ADHDDrugFrom 18 Years to 55 Years
Countries
United States
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Condition
ADHD
Drug study icon
CompletedNCT05220410

The Safety and Efficacy of Psilocybin in people with Treatment-resistant Depression and Chronic Suicide prevention

This study exists to better understand the safety of psilocybin treatment and how manageable it feels in practice. Researchers are trying to understand how people respond to psilocybin treatment in practice and what may need to be adjusted.

In Baltimore
Depression, SuicidalityDrugFrom 18 Years to 65 Years
Countries
United States
Sponsor
Sheppard Pratt Health System
Condition
Depression, Suicidality
Drug study icon
CompletedNCT05312151

Safety study of COMP360 in PTSD

This study is completed in the United States and in the United Kingdom. It is testing COMP360 for PTSD.

Multiple locations, including Rockville
PTSDDrugOver 18 Years
Countries
United States, United Kingdom
Sponsor
COMPASS Pathways
Condition
PTSD
Drug study icon
Active Not RecruitingNCT04950868

Effectiveness of quetiapine in depression

This study is active but not recruiting in Canada. It is testing quetiapine for depression.

In London
DepressionDrugFrom 18 Years to 45 Years
Countries
Canada
Sponsor
Verinder Sharma
Condition
Depression
Data coverage

Public registry coverage is progressing

HopeStage gathers information about mental health clinical trials from the public registries we currently index. We are progressively improving registry coverage, but this does not mean that every study in the world is already included.